{"transactions":[{"id":704004,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-23T22:52:47.000Z","date":"2026-07-22","kind":"grant","planned":false,"acquired":true,"shares":30500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":30500,"derivative":{"exercise_price":2.17,"expiration_date":"2036-07-22","underlying":"Common Stock","underlying_shares":30500},"source":{"system":"sec-edgar","filing":"0001965585-26-000006","document":"wk-form4_1784847165.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000196558526000006/wk-form4_1784847165.xml","form_type":"4"}},{"id":890256,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T21:15:50.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 19, 2026. The 160,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer."}],"balance_after":160000,"derivative":{"exercise_price":10.56,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001193125-26-061385","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526061385/ownership.xml","form_type":"4"}},{"id":1124277,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-06-03T20:00:33.000Z","date":"2025-05-31","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 72,000 shares of common stock."}],"balance_after":110400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-05-31","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0000950170-25-080885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025080885/ownership.xml","form_type":"4"}},{"id":1209189,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":18750,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209188,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":false,"shares":63813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024."}],"balance_after":11187,"derivative":{"exercise_price":3.91,"expiration_date":"2030-09-22","underlying":"Common Stock","underlying_shares":63813},"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209187,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis."}],"balance_after":0,"derivative":{"exercise_price":3.21,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209186,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"grant","planned":true,"acquired":true,"shares":38400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied."}],"balance_after":38400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-03-10","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":38400},"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209185,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":4350,"price":7.1498,"value":31101.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.14 to $7.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":76900,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209184,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":76963,"price":6.7276,"value":517776.2788,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.14 to $7.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":81250,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209183,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":true,"shares":31250,"price":0.511,"value":15968.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."}],"balance_after":158213,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209182,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":true,"shares":63813,"price":3.91,"value":249508.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."}],"balance_after":126963,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209181,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":true,"shares":17500,"price":3.21,"value":56175.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."}],"balance_after":63150,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1255140,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T21:00:10.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":225500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 225,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":225500,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":225500},"source":{"system":"sec-edgar","filing":"0000950170-25-024114","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025024114/ownership.xml","form_type":"4"}},{"id":1637596,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T21:43:59.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 15, 2024. The 175,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028."}],"balance_after":175000,"derivative":{"exercise_price":2.38,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-24-016465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024016465/ownership.xml","form_type":"4"}},{"id":1847557,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T20:00:12.000Z","date":"2023-06-20","kind":"exercise","planned":false,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":50000,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001209191-23-038744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123038744/doc4.xml","form_type":"4"}},{"id":1847556,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-06-21T20:00:12.000Z","date":"2023-06-20","kind":"exercise","planned":false,"acquired":true,"shares":6250,"price":0.511,"value":3193.75,"ownership":{"direct":true},"balance_after":45650,"source":{"system":"sec-edgar","filing":"0001209191-23-038744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123038744/doc4.xml","form_type":"4"}},{"id":1962611,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-08T21:00:28.000Z","date":"2023-03-07","kind":"exercise","acquired":false,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":56250,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001209191-23-017148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123017148/doc4.xml","form_type":"4"}},{"id":1962610,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-08T21:00:28.000Z","date":"2023-03-07","kind":"exercise","acquired":true,"shares":18750,"price":0.511,"value":9581.25,"ownership":{"direct":true},"balance_after":39400,"source":{"system":"sec-edgar","filing":"0001209191-23-017148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123017148/doc4.xml","form_type":"4"}},{"id":2010499,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-16T22:30:30.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2023. The 100,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 16, 2024 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 16, 2027."}],"balance_after":100000,"derivative":{"exercise_price":2.67,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-010190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123010190/doc4.xml","form_type":"4"}}]}